Moleculin Biotech, Inc. (MBRX) 披露:MIRACLE试验A部分招募预计2026年第三季度完成

美股速递
May 13

根据提交给美国证券交易委员会(SEC)的文件,Moleculin Biotech, Inc. 宣布其MIRACLE临床试验的A部分患者招募工作正按计划推进,目标是在2026年第三季度完成。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10